Hot on the heels of a terrific pun and blog post about the use of Tocilizumab, capturing all the intrigue, hope and caution with the potential use of this novel therapeutic […]
Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s Read More
We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine
JC: Lopinavir/Ritonavir in the treatment of COVID-19 Read More
As we near the end of 2020, it is worth taking a moment to reflect on what a year it has been. At the beginning of the year we were
JC: Azithromycin in patients hospitalised with COVID-19 Read More
A defining feature of the COVID-19 pandemic has been the wide spectrum of clinical presentations, ranging from asymptomatic viremia to life-threatening illness.1 Factors such as advancing age and co-morbid status have
The Emerging Evidence for a Genetic Susceptibility to Severe Covid-19. St Emlyn’s Read More
A core skill in emergency medicine is in the identification and classification of risk categories for the patients we see. For many conditions we have derived, validated and refined scoring
Risk stratification in the ED for COVID19 patients: The PRIEST study. St Emlyn’s Read More
I am sure many of you saw the breaking news on the BBC the other week, about a new wonderdrug to strengthen our defences against the tidal wave that is
Tocilizumaybe? Immune modulation in COVID-19 Read More
This week Simon and Rick got together to talk through the latest technologies, uses and performance of COVID-19 testing. We think it’s a really useful listen to understand the strengths
Understanding COVID-19 testing with Rick Body. St Emlyn’s Read More
This month the BMJ has published a trial on the use of convalescent plasma in the treatment of admitted patients with COVID-19 (the PLACID trial). Convalescent plasma therapy basically takes
JC: Convalescent plasma in COVID 19 patients. Read More
